PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28919867-4 2017 The selective CCK A receptor antagonist loxiglumide (100 muM) completely abolished the CCK-8 induced FA uptake. loxiglumide 40-51 cholecystokinin Mus musculus 14-17 9368707-0 1997 Cholecystokinin antagonistic activities of loxiglumide. loxiglumide 43-54 cholecystokinin Mus musculus 0-15 9368707-3 1997 Orally administered loxiglumide also antagonized the CCK-induced gallbladder emptying in mice. loxiglumide 20-31 cholecystokinin Mus musculus 53-56 9368707-4 1997 Furthermore, egg yolk-stimulated gallbladder emptying in mice was also inhibited by loxiglumide, indicating that this agent antagonizes not only exogenous but also endogenous CCK. loxiglumide 84-95 cholecystokinin Mus musculus 175-178 9368707-5 1997 These results demonstrate that loxiglumide is an intravenously and orally effective, potent CCK antagonist. loxiglumide 31-42 cholecystokinin Mus musculus 92-95 8586382-8 1995 The inhibitory effect of loxiglumide on omeprazole-induced increase in serum gastrin might be explained by recent findings which showed that CCK-A antagonists can stimulate gastric acid secretion probably due to a reduction of the inhibitory effect of basal CCK on the D-cell and its somatostatin release. loxiglumide 25-36 cholecystokinin Mus musculus 141-144 8586382-8 1995 The inhibitory effect of loxiglumide on omeprazole-induced increase in serum gastrin might be explained by recent findings which showed that CCK-A antagonists can stimulate gastric acid secretion probably due to a reduction of the inhibitory effect of basal CCK on the D-cell and its somatostatin release. loxiglumide 25-36 cholecystokinin Mus musculus 258-261